Optic nerve glioma or optic glioma or juvenile pilocytic astrocytoma is a type of brain tumour typically affecting the optic nerve cells. Optic nerve gliomas are sluggish developing, uncommon and frequently determined in youngsters. Its incidence in individuals over age 20 is quite rare and any other occurrence is associated with the genetic sickness neurofibromatosis type 1, or nf1 in about 30% of the cases.
The Global Optic Nerve Glioma Market is expected to reach US$ 350 million by 2023, and the market is projected to grow at a CAGR of ~ 3.2 % during the forecast period 2017-2023.
Symptoms of an optic nerve glioma are nausea and vision disturbances, vomiting, balance problems, involuntary eye movements, memory impairment, delay in growth etc. daytime sleepiness is also witnessed in a large number of patients. The pressure exerted by these tumours may cause secondary effects such as hormonal problems due to effects on the pituitary gland. Optic nerve gliomas comprise about 1% of all intracranial tumours.
About 10% of optic nerve gliomas are placed inside an optic nerve, one 0.33 in both optic nerve and chiasm which is an area wherein the left and proper optic nerves cross and approximately one third involve the chiasm itself. The final one fourth optic nerve gliomas are within the hypothalamus and approximately five .5% gliomas are multi-centric.
Product development and development of novel drugs is the most attractive strategy for the optic nerve glioma industry. As there is no effective treatment for malignant optic nerve gliomas, advent of any novel drug will have a remarkable effect on the existing treatment market. Any novel drug is expected to be a market leader with minimum marketing expenditure. The high development cost of novel anticancer drugs is a constraint on the market. Thus, pioneering in the drug development can pose to benefit the new entrants of the market.
Access Sample Copy @ https://www.marketresearchfuture.com/sample_request/4152 .
Key players profiled in the report are Emcure pharmaceuticals ltd., Sigma-Aldrich Co., ThermoFisher Scientific Inc., Pfizer Inc., Taj Pharmaceuticals Limited, Novartis International AG, Teva Pharmaceutical Industries Ltd, GE Healthcare, Siemens Healthcare, Philips Healthcare, Shimadzu Corporation, Toshiba Medical Systems Corporation and others and others.
The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new technology in the US drives the global optic nerve glioma market. Also, concentration of major research companies and cancer research sector in the developed countries of this region is adding fuel to the market.
Europe is the second largest market in the world due to high income and healthcare penetration.
Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing industrial sector during the forecast period.
Get Attractive Discount @ https://www.marketresearchfuture.com/check-discount/4152 .
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
+1 646 845 9312